SWP
PETX

Stratos Wealth Partners’s Aratana Therapeutics, Inc. PETX Stock Holding History

Stratos Wealth Partners’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-500
Closed -$3K – 3304
2017
Q4 		$3K Buy
+500
New +$3.06K ﹤0.01% 2570

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Stratos Wealth Partners's PETX Position: Q1 2018 in Review

Stratos Wealth Partners sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2018, closing a stake of 500 shares — an estimated $3K sold.

Stratos Wealth Partners first reported a position in PETX in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 103 funds tracked by Wall St. Rank hold PETX as of Q1 2018.

  • Stratos Wealth Partners reported no remaining Aratana Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 500 Aratana Therapeutics, Inc. shares in Q1 2018, an estimated $3K.
  • Stratos Wealth Partners first reported a position in Aratana Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Stratos Wealth Partners's Aratana Therapeutics, Inc. position peaked at $3K in Q4 2017.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2018.

Based on Stratos Wealth Partners's 13F filing for Q1 2018, filed 10 May 2018.